Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

MedImmune Warned On U.K. Vaccine Plant

June 4, 2007 | A version of this story appeared in Volume 85, Issue 23

FDA says MedImmune had not adequately addressed manufacturing issues at a plant in Liverpool, England, that makes FluMist nasal flu vaccine. MedImmune was alerted by FDA in December of inspected batches that exceeded limits for live organism content. The agency is working with MedImmune to resolve the issue and says it does not foresee a shortage of vaccine for the 2007-08 flu season. According to MedImmune, the action does not affect its pending acquisition by AstraZeneca. In 2004, vaccine production at Chiron's Liverpool plant was halted by British authorities after contaminated vaccine was found. The move led to a shortage of vaccine in the U.S.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.